↓ Skip to main content

Dove Medical Press

3-Coumaranone derivatives as inhibitors of monoamine oxidase

Overview of attention for article published in Drug Design, Development and Therapy, October 2015
Altmetric Badge

Mentioned by

twitter
1 X user
facebook
1 Facebook page

Readers on

mendeley
21 Mendeley
Title
3-Coumaranone derivatives as inhibitors of monoamine oxidase
Published in
Drug Design, Development and Therapy, October 2015
DOI 10.2147/dddt.s89961
Pubmed ID
Authors

Adriaan S Van Dyk, Jacobus P Petzer, Anél Petzer, Lesetja J Legoabe

Abstract

The present study examines the monoamine oxidase (MAO) inhibitory properties of a series of 20 3-coumaranone [benzofuran-3(2H)-one] derivatives. The 3-coumaranone derivatives are structurally related to series of α-tetralone and 1-indanone derivatives, which have recently been shown to potently inhibit MAO, with selectivity for MAO-B (in preference to the MAO-A isoform). 3-Coumaranones are similarly found to selectively inhibit human MAO-B with half-maximal inhibitory concentration (IC50) values of 0.004-1.05 µM. Nine compounds exhibited IC50<0.05 µM for the inhibition of MAO-B. For the inhibition of human MAO-A, IC50 values ranged from 0.586 to >100 µM, with only one compound possessing an IC50<1 µM. For selected 3-coumaranone derivatives, it is established that MAO-A and MAO-B inhibition are reversible since dialysis of enzyme-inhibitor mixtures almost completely restores enzyme activity. On the basis of the selectivity profiles and potent action, it may be concluded that the 3-coumaranone derivatives are suitable leads for the development of selective MAO-B inhibitors as potential treatment for disorders such as Parkinson's disease and Alzheimer's disease.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 5%
Nigeria 1 5%
Unknown 19 90%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 38%
Other 2 10%
Student > Ph. D. Student 2 10%
Student > Bachelor 1 5%
Professor > Associate Professor 1 5%
Other 0 0%
Unknown 7 33%
Readers by discipline Count As %
Chemistry 3 14%
Biochemistry, Genetics and Molecular Biology 2 10%
Agricultural and Biological Sciences 2 10%
Environmental Science 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Other 4 19%
Unknown 8 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2015.
All research outputs
#20,656,820
of 25,374,647 outputs
Outputs from Drug Design, Development and Therapy
#1,437
of 2,268 outputs
Outputs of similar age
#210,058
of 286,876 outputs
Outputs of similar age from Drug Design, Development and Therapy
#71
of 110 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,876 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 110 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.